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Translational Relevance. Among patients with CRC, there is considerable stage-independent variability in clinical outcome that is due, in part, to intratumor heterogeneity reflected in pathway-related molecular alterations. Given reported differences in the biology and prognosis of colon cancers by tumor site, we examined mutations in BRAF V600E and KRAS genes and the status of the DNA mismatch repair (MMR) system by site and their association with clinical outcome. Among patients with stage III colon carcinomas who participated in an adjuvant chemotherapy trial, we found primary tumor subsiterelated differences in frequencies of BRAF V600E and KRAS mutations as well as MMR. Tumors with mutations in BRAF V600E or KRAS codon 12 were more frequent in proximal colon whereas those with non-mutated BRAF/KRAS were enriched in the distal colon. Among tumors with KRAS mutations or deficient MMR, differences in patient outcome were found by tumor site, suggesting that interpretation should occur in the context of tumor location.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer worldwide and is a leading cause of cancer-related death (1) . The majority of colon cancers, especially distal cancers, display chromosomal instability (CIN) in association with frequent loss of heterozygosity and aneuploidy (2) . CIN tumors are enriched in KRAS mutations that occur as early events during tumorigenesis (3) . Alternatively, a subset of CRCs have microsatellite instability (MSI) and hypermutation due to deficient DNA mismatch repair (dMMR) (4) . These tumors most commonly develop dMMR due to epigenetic inactivation of the MLH1 MMR gene and the CpG island methylator phenotype (CIMP), along with frequent oncogenic BRAF (V600E) mutations (5, 6) . Colon cancers with BRAF V600E , including those with dMMR, are believed to arise via a serrated neoplasia pathway named for the pattern of mucosal crypts in precursor polyps, and have a strong predilection for the proximal colon (7) . Mutations in BRAF V600E are mutually exclusive with KRAS, and both lead to the activation of MEK/ERK signaling pathway (3, 8) that promotes tumor progression. While BRAF mutation is associated with adverse outcome in the metastatic CRC (9, 10) , less is known about its association or that of KRAS with patient outcome in earlier stage disease.
The primary site of colon cancer is typically categorized as located proximal to the splenic flexure, at or distal to this flexure, or in the rectum based upon their embryological origin. Mutations in BRAF V600E and dMMR are known to be enriched in cancers of the proximal colon (9, 10), although their subsite distribution and that of KRAS remain unknown. While the mechanisms underlying tumor site/subsite-related biological differences are poorly understood, distal colon cancers show more frequent chromosomal aberrations whereas proximal cancers have higher mutation rates even after excluding the subset of hypermutated dMMR tumors (11) . There is a need to examine the subsite distribution of relevant molecular alterations and to examine their prognostic association by anatomic site to gain biologic insights and further guide prognostication. Mortality rates have been reported to be higher in proximal compared to distal colon cancers, including lymph node-positive, i.e., stage III, tumors (12) (13) (14) .
However, studies examining tumor site and prognosis generally lack data on key molecular markers that precludes their adjustment in multivariable models, and cohorts have not received standard adjuvant chemotherapy with the FOLFOX regimen.
In this report, we examined the frequency of molecular alterations by primary tumor subsite, and tested the hypothesis that the association of BRAF V600E and KRAS mutations with clinical outcome depends on their anatomic site within the colon. We also determined whether tumor site-related differences in clinical outcome persist after adjustment for BRAF V600E and KRAS mutations as well as by MMR status. Our study population consists of stage III colon cancers from an adjuvant chemotherapy trial that found no survival benefit for the addition of cetuximab to standard FOLFOX chemotherapy (15) . In contrast to prior reports in the N0147 cohort that were limited to tumors lacking KRAS mutations based upon the primary endpoint analysis (15, 16) , the current study includes patients with KRAS mutated tumors and reports mature overall survival (OS) data for the trial.
Research. 
METHODS

Study Population
Patients with resected, stage III (any T, N1 or N2, M0) colon adenocarcinomas participated in a phase III study (15) 
DNA Mismatch Repair Protein Expression
MMR protein (MLH1, MSH2 and MSH6) expression was analyzed in formalin-fixed, paraffin-embedded tumor sections as previously described (19) values <0.05 were considered statistically significant and were not adjusted for multiple comparisons. Analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary NC) and R version 3.02 (22) .
RESULTS
Patient, Tumor, and Clinicopathologic Characteristics
Characteristics of the study population of stage III colon cancer patients (N=3,018) are shown stratified by primary tumor site or subsite and by molecular markers ( Fig. 1 ). KRAS mutations were more evenly distributed across the subsites compared to BRAF V600E mutations or dMMR. The highest rates of KRAS codon 12 mutations were found in cancers at the cecum and splenic flexure, whereas the rate of KRAS codon 13 mutations was similar across tumor subsites (Fig. 1) . Cancers lacking mutations in KRAS and BRAF V600E were significantly more likely to be located in the distal colon with a progressive decrease from sigmoid to transverse
colon. An abrupt increase in BRAF V600E mutant cancers was seen beginning in the transverse colon and extending to the cecum with a peak in frequency at the hepatic flexure (Fig. 1) . The distribution of BRAF V600E mutations in tumors directly paralleled that of dMMR with both being highest in tumors at the hepatic flexure followed by the ascending colon and cecum (Table 1) .
Interestingly, the distribution of mutant BRAF V600E tumors by subsite was similar in dMMR and pMMR tumors. Tumors with dMMR and a non-mutated BRAF gene were also predominantly located in the proximal colon (Fig. 1) . In contrast, pMMR tumors with non-mutated BRAF were more commonly distal with the highest rate detected in the sigmoid colon.
Association of Molecular Markers with Prognosis
Mutations in KRAS or BRAF V600E were each associated with significantly poorer time-torecurrence (TTR), disease-free survival (DFS) and overall survival (OS) in univariate models (all p<.0094) [Suppl (Fig. 2) . Univariately, dMMR was not significantly associated with the time-to-event variables (Suppl outcome by tumor site was found to be consistent with the overall cohort (Fig. 3) . Specifically, patients with distal vs proximal cancers with mutated vs non-mutated KRAS had poorer outcome (Fig. 3A) . The association of mutated vs non-mutated BRAF with adverse outcome was more evident in proximal cancers yet the interaction test did not reach statistical significance as previously indicated (Fig. 3B) . In the FOLFOX alone arm, the association of dMMR vs pMMR with better outcome variables was restricted to proximal cancers as was found in the overall cohort (Fig. 3C) . In distal tumors, the association of dMMR vs pMMR with significantly worse outcome did not achieve statistical significance in the FOLFOX alone arm.
Prognostic Impact of Primary Tumor Site
Tumors of the proximal (vs distal) colon were significantly associated with poorer outcome for TTR, DFS, and OS in the overall cohort after adjustment for covariates (all p<0.05;
Suppl significantly, and a similar trend was observed for TTR, with distal migration of the primary tumor following the anatomic order from cecum to sigmoid colon (i.e., cecum, ascending, hepatic flexure, transverse, splenic flexure, descending, and sigmoid) [TTR, p=0.0646; OS, p=0.0011] (Fig. 4) . Patients with cecal cancers had the worst outcome whereas those with sigmoid tumors had the best outcome as illustrated by Forest plots for TTR and OS (Fig. 4) .
Specifically, patients with cecal and ascending colon cancers had 5 year OS rates of 70% (66-74) and 74% (69-78) respectively, whereas OS rates for patients with descending or sigmoid cancers were 89% (83-94) or 85% (83-87) (Fig. 4) . Similar results were found for 5-year TTR by tumor site (cecum 67%, ascending 67%; descending 71%, sigmoid 73%).
DISCUSSION
We examined the association of mutations in BRAF V600E and KRAS in stage III colon carcinomas with primary tumor subsite from patients treated in a large adjuvant chemotherapy trial. KRAS exon 2 mutations were more evenly distributed throughout the colon than were cohort where the frequencies of BRAF V600E mutations, CIMP, and MSI-H increased linearly from the rectum to the ascending colon, although both studies found that KRAS mutations were most frequent in cecal cancers. Importantly, we found that the proximal colon predominance for BRAF V600E mutations persisted when the cohort was restricted to pMMR cancers, consistent with the earlier development of BRAF V600E -mutations that appear to develop in a site-specific manner during colonic tumorigenesis. BRAF mutant colon cancers are believed develop via the serrated neoplasia pathway from precursor lesions known as sessile serrated adenomas/polyps that are characterized by frequent BRAF mutations, CIMP-high, and proximal colon predominance (7) . Analysis of stage II and III colon cancers from the PETACC-3 adjuvant study (11, 27) and the TCGA series (4) also found higher rates of BRAF V600E and KRAS mutations in proximal vs distal colon cancers. While the mechanisms underlying the observed tumor siterelated differences in the mutation rates of these oncogenes and dMMR remain unknown, they may reflect specific mechanisms of carcinogenesis and/or differences in embryologic origin with the proximal colon derived from the midgut and the distal colon from the hindgut. In addition, differences in colonic microbiota have been found in the proximal and distal regions of the colon that may influence molecular events and host immune responses during carcinogenesis in a site-specific manner (28, 29 
is consistent with other studies (30) (31) (32) . Studies also indicate that BRAF V600E mutations are associated with worse patient survival after tumor recurrence (32-34); however, such an analysis in our cohort awaits more extended patient follow-up. In the overall cohort, we found that KRAS codon 12 mutations were significantly associated with worse outcome variables compared to tumors that were non-mutated for KRAS or BRAF. Mutations at codon 13 were also significantly associated with worse DFS as we reported previously (35) , and a strong trend for worse TTR and OS was also found. KRAS codon 13 mutations were of borderline significance for poorer DFS in the PETACC-8 adjuvant study that had identical treatment arms to our trial, yet had fewer codon 13 mutated tumors (136 vs 231) (36) . in a database from two nationwide prospective cohort studies, the lack of association of codon 13, in contrast to codon 12, mutations may also be due to sample size since only 108 codon 13-mutated colon cancers were analyzed (37) . Patients with dMMR cancers showed a statistically significant delay in TTR and showed a trend for better DFS (p=0.10) and OS (p=0.18) rates compared to patients with pMMR tumors. These data are consistent with other studies where the association of dMMR or MSI-H status with favorable prognosis is attenuated in stage III compared to stage II colon cancer patients treated with 5-FU-based adjuvant chemotherapy (38) . Among stage III disease, the attenuated effect of dMMR on survival may be related to our finding of a similar proportion of dMMR and pMMR N2 tumors where both N2 subgroups showed poorer outcome in the N0147 cohort (39).
We tested the hypothesis that the association of KRAS and BRAF V600E mutations with clinical outcome depends on the anatomic site of the primary tumor. In the overall cohort, we
found a statistically significant interaction between mutations in KRAS, but not BRAF V600E , and primary tumor site for OS. Specifically, KRAS mutations were associated with adverse outcome in distal vs proximal cancers that reached statistical significance for OS. Non-mutated BRAF/KRAS tumors were enriched in distal tumors, and we previously reported that this patient subgroup had a favorable clinical outcome (35) . We also observed a statistically significant interaction between MMR status and tumor site for TTR, DFS and OS. Specifically, proximal but not distal dMMR cancers were associated with significantly better outcomes. In a prior study,
we also reported an interaction between MMR status and tumor site for survival in patients treated with 5-FU/leucovorin alone or combined with irinotecan (CALGB 89803) (16) .
Since cetuximab has no role in the adjuvant therapy of colon cancer (15, 24) , only data An unresolved issue is whether primary tumor site-related differences in outcome persist after adjustment for MMR, KRAS and BRAF status. We found that tumor site was independently associated with prognosis after adjustment for BRAF V600E and KRAS mutations as well as for MMR status in the overall cohort. Further analysis by tumor subsite revealed that anatomical migration of the primary tumor from the proximal to distal colon was significantly associated with a stepwise improvement in overall survival. Patients with cecal cancers had the worst outcome whereas those located in the sigmoid colon had the best survival rates. While the specific explanation for this finding is unknown, analysis of colon cancers from the PETACC-3 (11) and TCGA (4) studies found that proximal cancers have higher mutation rates even after excluding dMMR tumors, and potentially more deleterious mutations. 
